What is Dianthus Therapeutics's EBITDA margin?

Dianthus Therapeutics (DNTH) reported EBITDA margin of -4,554.8% in Q3 2025.

How has Dianthus Therapeutics's EBITDA margin changed year-over-year?

Dianthus Therapeutics's EBITDA margin decreased by 195.1% year-over-year, from -1,543.3% to -4,554.8%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Dianthus Therapeutics DNTH EBITDA margin

EBITDA margin at other companies

Johnson & JohnsonJNJ

34.4%+2.7pp

AmgenAMGN

41.5%+3.4pp

Spyre Therapeutics, Inc.SYRE

-17,462.5%-18,885pp

Kymera TherapeuticsKYMR

-681.6%+642pp

Protagonist TherapeuticsPTGX

-190.4%-204pp

TG TherapeuticsTGTX

21.4%+5.9pp

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

ebitda/total revenue=-4,554.8%

Based on trailing twelve months.

The official record: Dianthus Therapeutics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's EBITDA margin?: Dianthus Therapeutics (DNTH) reported EBITDA margin of -4,554.8% in Q3 2025.
How has Dianthus Therapeutics's EBITDA margin changed year-over-year?: Dianthus Therapeutics's EBITDA margin decreased by 195.1% year-over-year, from -1,543.3% to -4,554.8%.
What does EBITDA margin mean?: EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.